Figure 4From: A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice Whole brain TACs of [ 11 C]erlotinib (left) and [ 18 F]afatinib (right) before and after tariquidar pre-treatment. TACs are averaged over three animals.Back to article page